<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979377</url>
  </required_header>
  <id_info>
    <org_study_id>DM1PCOS</org_study_id>
    <nct_id>NCT04979377</nct_id>
  </id_info>
  <brief_title>Prevalence of Hyperandrogenism in Type 1 Diabetes</brief_title>
  <official_title>Prevalence of Hyperandrogenism in Young Women With Type 1 Diabetes and Study of the Underlying Pathophysiological Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alcala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to estimate the prevalence of functional ovarian hyperandrogenism&#xD;
      [idiopathic hyperandrogenism, idiopatic hirsutism, and polycystic ovary syndrome (PCOS)] in&#xD;
      adult patients with type 1 diabetes (T1DM) in an observational cross-sectional study. Study&#xD;
      population is comprised of premenopausal adult women with a diagnosis of T1DM, consecutively&#xD;
      recruited from a Diabetes outpatient clinic at a tertiary hospital in Spain, Europe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of&#xD;
      reproductive age, with an estimated prevalence of 6-15% of the general population worldwide.&#xD;
      This heterogeneous syndrome has significant cardio-metabolic, reproductive, and&#xD;
      psycho-emotional consequences, and therefore, a prompt recognition and management is of&#xD;
      paramount importance for these women. Despite hyperandrogenism is the cornerstone in the&#xD;
      pathophysiology of PCOS, this derangement is closely related to insulin resistance,&#xD;
      compensatory hyperinsulinemia, and abdominal adiposity. Hyperinsulinemia increases androgen&#xD;
      secretion by co-stimulating besides gonadotropins both ovary and adrenal steroidogenesis,&#xD;
      which leads to predominant visceral/abdominal fat deposition, and further contributes to&#xD;
      insulin resistance and hyperinsulinemia. In addition, PCOS has been classically associated&#xD;
      with metabolic alterations such as for overweight/obesity and type 2 diabetes mellitus.&#xD;
      However, type 1 diabetes mellitus (T1D) results from autoimmune-mediated destruction of the&#xD;
      pancreas, causing a complete insulin lack in most patients. Intensive insulin therapy - a&#xD;
      mandatory iatrogenic hyperinsulinism -, while improving chronic glycemic control and&#xD;
      prognosis, has led in recent years to the appearance of &quot;new&quot; reproductive consequences in&#xD;
      these patients, such as functional hyperandrogenism and menstrual irregularity. This&#xD;
      association is expected from the stimulation of ovarian androgen production by exogenous&#xD;
      insulin, which reaches the ovary in supraphysiological concentrations. However, these studies&#xD;
      present with a high heterogeneity, and prevalence rates significantly vary depending on&#xD;
      several variables such as the criteria used for PCOS diagnosis, race/ethnicity, age of the&#xD;
      study population, and the prevalence of obesity, among others. In 2016, a systematic review&#xD;
      assessing the prevalence of PCOS in T1D was published, including 475 women with T1D from 9&#xD;
      studies. The results showed an overall prevalence of PCOS about 24% in T1D, higher than&#xD;
      reported in the general population. Other hyperandrogenic traits such as hirsutism (25%),&#xD;
      hyperandrogenaemia (24%), or ovulatory dysfunction (33%) were also common. Although PCOS is&#xD;
      one of the most common comorbidities in patients with T1D, there are a limited number of&#xD;
      publications in the literature. In summary, PCOS and functional hyperandrogenism remain a&#xD;
      condition to be explored thoroughly in these patients.&#xD;
&#xD;
      The investigators hypothesize that the prevalence of functional hyperandrogenism including&#xD;
      PCOS in Spanish women with T1D is higher than in women from the general population.&#xD;
      Furthermore, signs and symptoms of hyperandrogenism, and hyperandrogenemia may be milder in&#xD;
      patients with T1D compared to hyperandrogenic women from the general population. Moreover,&#xD;
      the occurrence of PCOS in these women may be influenced by insulin dose, duration of&#xD;
      diabetes, and chronic metabolic control.&#xD;
&#xD;
      The main objective of this study is to determine the actual prevalence of PCOS in&#xD;
      premenopausal women with T1DM, according to different diagnostic criteria/PCOS phenotypes&#xD;
      [classic PCOS (classic NIH criteria), hyperandrogenic PCOS (AES-PCOS criteria), and/or&#xD;
      inclusive ESHRE-ASRM/Rotterdam criteria]. As secondary goals, the investigators also aim to&#xD;
      describe: i) the hyperandrogenic traits associated with PCOS in women with T1DM; and ii) the&#xD;
      metabolic-T1D related parameters in women with or without hyperandrogenism.&#xD;
&#xD;
      Sample size calculation: Sample size analysis used the online sample size and power&#xD;
      calculator from the Program of Research in Inflammatory and Cardiovascular Disorders,&#xD;
      Institut Municipal d'Investigació Mèdica, Barcelona, Spain&#xD;
      (https://www.imim.cat/ofertadeserveis/software-public/granmo/). Considering previous data on&#xD;
      prevalence of SOP in adolescents and adult women with T1D according to ESHRE-ASRM/Rotterdam&#xD;
      criteria, the investigators concluded that 150 participants would be needed to assume an&#xD;
      expected proportion of 40%, with an absolute precision of 5% at both sides of the proportion,&#xD;
      and an asymptotic bilateral 95% confidence interval, and with an estimated replacement rate&#xD;
      of 10%.&#xD;
&#xD;
      Statistical analysis: Continuous variables will be expressed as mean ± SD with its respective&#xD;
      95% confidence intervals (95%CI). Normality of continuous variables will be checked by the&#xD;
      Kolmogorov-Smirnov test, and ensured by applying logarithmic transformations. the&#xD;
      investigators will use non-parametric tests to analyse variables that remained skewed even&#xD;
      after transformation. The differences in means will be analysed by Student t or Mann-Whitney&#xD;
      U tests. Discrete variables will be showed according to their absolute, relative frequency,&#xD;
      and 95%CI determined using the Wilson method without continuity correction. The differences&#xD;
      between proportions will be estimated using the χ2 or Fisher's exact tests. Correlation&#xD;
      analysis will be used to evaluate putative association between continuous variables. Finally,&#xD;
      multiple linear an binary logistic regression full and stepwise models (probability for entry&#xD;
      ≤0.05, probability for removal ≥0.10) will be performed to ascertain the main determinants of&#xD;
      predetermined outcomes. The statistical significance will be set at the P &lt; 0.05 level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">January 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of PCOS in T1DM</measure>
    <time_frame>2020-2022</time_frame>
    <description>Prevalence of PCOS in women with T1DM according to ESHRE-ASRM/Rotterdam criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of classic PCOS in T1DM</measure>
    <time_frame>2020-2022</time_frame>
    <description>Prevalence of PCOS in women with T1DM according to classic NIH criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of hyperandrogenic PCOS in T1DM</measure>
    <time_frame>2020-2022</time_frame>
    <description>Prevalence of PCOS in women with T1DM according to AES-PCOS criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of related traits in women with T1D</measure>
    <time_frame>2020-2022</time_frame>
    <description>Prevalence of related hyperandrogenic traits (idiopatic hirsutism, hyperandrogenemia, oligomenorrhea and isolated polycytic ovarian morphology) in women with T1DM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence fo the onset of type 1 diabetes on hyperandrogenism</measure>
    <time_frame>2020-2022</time_frame>
    <description>To assess the influence of the timing of diagnosis of type 1 diabetes in the appearance of hyperandrogenism, and also the possible effect of duration of diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Insulin Requirements on hyperandrogenism</measure>
    <time_frame>2020-2022</time_frame>
    <description>To describe daily insulin requirements and their influence on functional hyperandrogenism occurrence. We also aim to determine the effect of the chronic metabolic control in PCOS appearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of metabolic control on hyperandrogenism</measure>
    <time_frame>2020-2022</time_frame>
    <description>To describe the influence of metabolic control (A1c) on functional hyperandrogenism occurrence. We also aim to determine the effect of the chronic metabolic control in PCOS appearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of body composition on hyperandrogenism</measure>
    <time_frame>2020-2022</time_frame>
    <description>To evaluate the influence of risk factors body composition in the occurrence of ovarian hyperandrogenism and PCOS in women with type 1 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of hyperandrogenism on insulin requirements</measure>
    <time_frame>2020-2022</time_frame>
    <description>To describe the influence of hyperandrogenism on metabolic control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of hyperandrogenism on A1c</measure>
    <time_frame>2020-2022</time_frame>
    <description>To describe the influence of hyperandrogenism on metabolic control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of hyperandrogenism on mean glucose (GCM)</measure>
    <time_frame>2020-2022</time_frame>
    <description>To describe the influence of hyperandrogenism on metabolic control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of hyperandrogenism on time in range (GCM)</measure>
    <time_frame>2020-2022</time_frame>
    <description>To describe the influence of hyperandrogenism on metabolic control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of hyperandrogenism on chronic complications</measure>
    <time_frame>2020-2022</time_frame>
    <description>To describe the influence of hyperandrogenism on the frequency of chronic complications related to type 1 diabetes mellitus</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Hyperandrogenism</condition>
  <condition>Hirsutism</condition>
  <condition>Oligomenorrhea</condition>
  <condition>Ovulation Disorder</condition>
  <arm_group>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <description>One-hundred and fifty women aged from 18 to 45 years old consecutively recruited from a type 1 diabetes clinic at a tertiary hospital of Madrid, Spain</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical hyperandrogenism assessment</intervention_name>
    <description>Modified Ferriman-Gallwey scale</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Hirsutism score</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Total testosterone (ng/dL)</intervention_name>
    <description>Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Sex steroid profile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>A1c (%)</intervention_name>
    <description>High Performance Liquid Chromatography (HPLC)</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Metabolic control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Total cholesterol</intervention_name>
    <description>Determined by enzymatic methods</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Lipid profile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Body mass index (BMI) (kg/m2)</intervention_name>
    <description>Defined as body weight divided by the square of body height, and expressed in kg/m2</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Anthropometrics and body composition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Frequency of chronic vascular complications [n (%)]</intervention_name>
    <description>Retinopathy, nephropathy, neuropathy, and macrovascular disease.</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Polycystic ovary morphology</intervention_name>
    <description>Sonographic assessment</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiovascular autonomic reflex tests (CARTs)</intervention_name>
    <description>Cardioautonomic function assessement by Vital scan HW7-HW6T:</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Cardiovascular function</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sex hormone-binding globulin (SHBG) (nmol/L)</intervention_name>
    <description>Circulating SHBG (IQL) at follicular phase</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Sex steroid profile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dehydroepiandrosterone-sulphate (IQL) (ng/mL)</intervention_name>
    <description>Circulating DHEAS (IQL) at follicular phase</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Sex steroid profile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Waist circumference (cm)</intervention_name>
    <description>Waist circumference measurement made at the top of the iliac crest</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Anthropometrics and body composition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Waist-to-hip ratio</intervention_name>
    <description>Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Anthropometrics and body composition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Body composition</intervention_name>
    <description>Vital Scan HW7-HW6T</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Bioimpedanciometry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Mean glucose (mg/dL)</intervention_name>
    <description>Continuous glucose monitoring (GCM) records</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Metabolic control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Time in target range (hours)</intervention_name>
    <description>Continuous glucose monitoring (GCM) records</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Metabolic control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Time in hyperglycemia (hours)</intervention_name>
    <description>Continuous glucose monitoring (GCM) records</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Metabolic control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Insulin dose (UI/Kg)</intervention_name>
    <description>Daily insulin dose divided by body weight</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Metabolic control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Insulin sensitivity</intervention_name>
    <description>Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Estimated glucose disposal rate (eGDR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>High-density lipoprotein (HDL) (mg/dL)</intervention_name>
    <description>Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>HDL-cholesterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Low-density lipoprotein (LDL) (mg/dL)</intervention_name>
    <description>Estimated by the Friedewald's equation.</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Lipid profile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Triglycerides (mg/dL)</intervention_name>
    <description>Determined by enzymatic methods</description>
    <arm_group_label>Adult premenopausal women with type 1 diabetes mellitus</arm_group_label>
    <other_name>Lipid profile</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma and DNA archive samples for further analyses. Registry number (Instituto de&#xD;
      Salud Carlos III): C.0005860&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Premenopausal women with T1DM consecutively recruited from a Diabetes outpatient clinic at&#xD;
        a tertiary hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 45 years old&#xD;
&#xD;
          -  Type 1 diabetes diagnosed at least 1 year before the inclusion in the study. Diagnosis&#xD;
             confirmed by positive autoimmunity (GAD-65 or IA2) and insulin deficiency.&#xD;
&#xD;
          -  Treatment with subcutaneus insulin therapy (multiple dose or continuous subcutaneous&#xD;
             insulin infusion).&#xD;
&#xD;
          -  Menarche at least 2 years before the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Honey moon period.&#xD;
&#xD;
          -  Altered thyroid hormone or prolactin levels.&#xD;
&#xD;
          -  Congenital adrenal hyperplasia.&#xD;
&#xD;
          -  Severe chronic disease.&#xD;
&#xD;
          -  Oral contraceptive or glucocorticoid therapy in the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Luque-Ramírez, PhD, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>CIBERDEM, Instituto de Salud Carlos III</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Héctor F Escobar-Morreale, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alcalá</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ane Bayona Cebada, MD</last_name>
    <phone>+34913369029</phone>
    <email>abayona13@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Fernández Durán</last_name>
    <phone>+34913368056</phone>
    <email>elena.fernandezd@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ane Bayona Cebada, MD</last_name>
      <phone>+34913368056</phone>
      <email>abayona13@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Elena Fernández-Durán</last_name>
      <phone>+34913368056</phone>
      <email>elena.fernandezd@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ane Bayona Cebada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lía Nattero-Chávez, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edurne Lecumberri Pascual, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Escobar-Morreale HF, Roldán B, Barrio R, Alonso M, Sancho J, de la Calle H, García-Robles R. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2000 Nov;85(11):4182-7.</citation>
    <PMID>11095451</PMID>
  </reference>
  <reference>
    <citation>Roldán B, Escobar-Morreale HF, Barrio R, de La Calle H, Alonso M, García-Robles R, Sancho J. Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care. 2001 Jul;24(7):1297-9.</citation>
    <PMID>11423519</PMID>
  </reference>
  <reference>
    <citation>Codner E, Escobar-Morreale HF. Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2007 Apr;92(4):1209-16. Epub 2007 Feb 6. Review.</citation>
    <PMID>17284617</PMID>
  </reference>
  <reference>
    <citation>Escobar-Morreale HF, Roldán-Martín MB. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care. 2016 Apr;39(4):639-48. doi: 10.2337/dc15-2577. Review.</citation>
    <PMID>27208367</PMID>
  </reference>
  <reference>
    <citation>Codner E, Soto N, Lopez P, Trejo L, Avila A, Eyzaguirre FC, Iniguez G, Cassorla F. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2006 Jun;91(6):2250-6. Epub 2006 Mar 28.</citation>
    <PMID>16569737</PMID>
  </reference>
  <reference>
    <citation>Codner E, Iñíguez G, Villarroel C, Lopez P, Soto N, Sir-Petermann T, Cassorla F, Rey RA. Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. J Clin Endocrinol Metab. 2007 Dec;92(12):4742-6. Epub 2007 Sep 25.</citation>
    <PMID>17895317</PMID>
  </reference>
  <reference>
    <citation>Gaete X, Vivanco M, Eyzaguirre FC, López P, Rhumie HK, Unanue N, Codner E. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. Fertil Steril. 2010 Oct;94(5):1822-6. doi: 10.1016/j.fertnstert.2009.08.039. Epub 2009 Sep 30.</citation>
    <PMID>19796762</PMID>
  </reference>
  <reference>
    <citation>Codner E, Merino PM, Tena-Sempere M. Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update. 2012 Sep-Oct;18(5):568-85. doi: 10.1093/humupd/dms024. Epub 2012 Jun 17. Review.</citation>
    <PMID>22709979</PMID>
  </reference>
  <reference>
    <citation>Nattero-Chávez L, Alonso Díaz S, Jiménez-Mendiguchia L, García-Cano A, Fernández-Durán E, Dorado Avendaño B, Escobar-Morreale HF, Luque-Ramírez M. Sexual Dimorphism and Sex Steroids Influence Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes. Diabetes Care. 2019 Nov;42(11):e175-e178. doi: 10.2337/dc19-1375. Epub 2019 Sep 17.</citation>
    <PMID>31530659</PMID>
  </reference>
  <reference>
    <citation>Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. doi: 10.1093/humrep/dey256. Erratum in: Hum Reprod. 2019 Feb 1;34(2):388.</citation>
    <PMID>30052961</PMID>
  </reference>
  <reference>
    <citation>Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF, Norman RJ. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar-Apr;18(2):146-70. doi: 10.1093/humupd/dmr042. Epub 2011 Nov 6. Review. Erratum in: Hum Reprod Update. 2013 Mar-Apr;19(2):207.</citation>
    <PMID>22064667</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Manuel Luque Ramírez</investigator_full_name>
    <investigator_title>Co-Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Hyperandrogenism</keyword>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Hirsutism</keyword>
  <keyword>Ovulatory dysfunction</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Hirsutism</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Oligomenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data sets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Since study ending with no time limit restriction</ipd_time_frame>
    <ipd_access_criteria>Reasonable request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

